For the first time and in response to the COVID-19 outbreak, the National Institute of Allergy and Infectious Diseases (NIAID) together with the National Institute of General Medical Sciences (NIGMS) has activated the NIH Urgent Award mechanism. The targeted opportunity is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
NIH has taken an expanded approach in defining scientists from disadvantaged backgrounds, in an effort to encourage and enable more biomedical scientists. NIH determined that the criteria they were using in defining disadvantaged was too narrow; for example, what was considered low-income ($25,750 for a family of four) is actually considered severe poverty and represents an overly strict threshold, the reviewers found.
In recent weeks, three separate reviews of R&D grants and awards at NIH have shed new light on issues of minority and women representation among researchers and on potential conflicts of interest by investigators. NIH has been publicly working to address concerns about representation and trustworthiness among its investigators. While the results from these studies show that the agency has more work to do, the availability of this information speaks favorably to NIH's transparent approach to these conversations.
Home to the Research Triangle Park and top-tier research universities like Duke University and the University of North Carolina at Chapel Hill, the Durham-Chapel Hill metropolitan area led all regions in per capita NIH funding in FY 2018 and placed sixth in total funding that year, according to a new analysis by SSTI. This edition of Useful Stats looks at all NIH awards at the regional level over the five-year period between FY 2014 and FY 2018.
Home to the Research Triangle Park and top-tier research universities like Duke University and the University of North Carolina at Chapel Hill, the Durham-Chapel Hill metropolitan area led all regions in per capita NIH funding in FY 2018 and placed sixth in total funding that year, according to a new analysis by SSTI. This edition of Useful Stats looks at all NIH awards at the regional level over the five-year period between FY 2014 and FY 2018. Boston led all regions in total NIH funding in FY 2018, while NIH funding in the Washington, D.C., region increased by the greatest percentage over the five-year period among major metropolitan areas.
As the largest public funder of biomedical research in the world, NIH awards are of particular importance to the technology-based economic development community. Including new data for FY 2017 and FY 2018, this edition of Useful Stats serves as an update to an August 2017 article highlighting NIH awards by state over the past decade. In FY 2018, NIH awarded a total of $28.3 billion in funds to the 50 states and territories.
As the largest public funder of biomedical research in the world, NIH awards are of particular importance to the technology-based economic development community. Including new data for FY 2017 and FY 2018, this edition of Useful Stats serves as an update to an August 2017 article highlighting NIH awards by state over the past decade. In FY 2018, NIH awarded a total of $28.3 billion in funds to the 50 states and territories. Of the total amount awarded in 2018, slightly less than two thirds (65.3 percent) went to the top 10 states. This share is slightly lower than in 2017 (65.6 percent), the same as in 2014 (65.3 percent) and slightly higher than in 2009 (66.1 percent).
Are you looking to increase the success rate of your state’s SBIR/STTR proposals? If so, a reminder that applications for the Small Business Administration’s Federal and State Technology (FAST) Partnership Program are due next Friday, June 28, at 4 p.m. EDT. This program provides one-year funding to organizations executing programs related to SBIR/STTR outreach, technical assistance, or financial support.
A significant majority of SBIR and STTR grants awarded to small businesses from the National Institutes of Health in any given year end up in just a handful of states.
A significant majority of SBIR and STTR grants awarded to small businesses from the National Institutes of Health in any given year end up in just a handful of states. For example, the percentage of all 2017 SBIR/STTR awards made to companies in the 23 states and Puerto Rico eligible to participate for funding from NIH’s Institutional Development Award (IDeA) program was only 8 percent – 97 of the 1,218 awards made across all phases of both innovation funding programs. For comparison, the same states account for 15.8 percent of the estimated U.S. population in 2017. NIH wants to change that discrepancy.
One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate. NIH SBIR/STTR applications in Oregon (29 percent success rate), Vermont (25 percent success rate), and Wisconsin (23 percent success rate) were the most likely to be approved over the ten-year period from 2008 to 2017. Each of these states, as well as many others with high success rates, offer assistance with proposals such as technical support programs and Phase 0 grants.
SSTI is publishing a series of FY 2019 budget updates to match Congress’s unusually early action.
Congress is set to pass portions of the overall FY 2019 federal budget before the end of the current fiscal year, which has been rare over the last decade. To keep pace, SSTI will be running a series of FY 2019 budget updates. Part I is Energy and Water (including Regional Agencies), Legislative Branch, and Military Construction and Veterans Affairs. Part II is Defense with Labor and HHS, as well as a CR for the rest of the government through Dec. 7.
Approximately 30.2 percent of NIH-funded research studies produce false positive results that make those studies not replicable by other researchers, according to a recent study from researchers at Queensland University of Technology (AU). The authors of the study contend that the reproducibility crisis is driven by “publish or perish” incentives to increase the quantity of their papers at the cost of quality.